Shares of Neumora Therapeutics plummeted significantly following the disappointing announcement that its lead experimental drug candidate, navacaprant, failed to meet both the primary and key secondary endpoints in two separate Phase 3 clinical trials evaluating its efficacy for adults suffering from major depressive disorder. Because the therapy failed to demonstrate a statistically significant clinical advantage over a placebo control group, management made the strategic decision to completely discontinue the development program for navacaprant. To mitigate financial fallout, the company also announced a substantial workforce reduction of approximately thirty-five percent and shifted its clinical focus toward other early-stage pipeline assets.